Major stock indexes in the United States are showing mixed performance, with the Dow Jones Industrial Average rising while data-storage shares weigh on the Nasdaq. For investors willing to explore beyond established giants, penny stocks—often representing smaller or newer companies—offer intriguing opportunities. Despite their vintage name, these stocks can present underappreciated growth potential at lower price points, especially when backed by strong balance sheets and solid fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$3.04	$602.2M	✅ 3 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.87	$683.54M	✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)	$0.8639	$144.24M	✅ 4 ⚠️ 1 View Analysis >
LexinFintech Holdings (LX)	$3.08	$533.4M	✅ 4 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.28	$1.36B	✅ 4 ⚠️ 1 View Analysis >
CI&T (CINT)	$4.36	$578.98M	✅ 5 ⚠️ 0 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
VAALCO Energy (EGY)	$3.48	$375.33M	✅ 3 ⚠️ 3 View Analysis >
BAB (BABB)	$0.971762	$7.13M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$3.84	$87.45M	✅ 3 ⚠️ 2 View Analysis >

We're going to check out a few of the best picks from our screener tool.

Broadwind (BWEN)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Broadwind, Inc. manufactures and sells structures, equipment, and components for clean technology and specialized applications in the United States with a market cap of $77.26 million.

Operations: The company's revenue is derived from three main segments: Heavy Fabrications ($100.03 million), Gearing ($27.95 million), and Industrial Solutions ($26.75 million).

Market Cap: $77.26M

Broadwind, Inc., with a market cap of US$77.26 million, has shown significant earnings growth, reporting a net income of US$7.46 million for Q3 2025 compared to US$0.074 million the previous year. Despite its high share price volatility and low return on equity at 7.8%, the company benefits from stable debt levels with a net debt to equity ratio of 13.7%. However, its interest coverage is weak due to negative operating cash flow and one-off gains impacting financial results. Recent developments include securing US$11 million in new orders and raising revenue guidance for 2025 to between US$155-160 million.

Commerce.com (CMRC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Commerce.com, Inc. provides a software-as-a-service e-commerce platform for brands and retailers across multiple regions globally, with a market cap of $348.62 million.

Operations: The company generates $339.86 million in revenue from its Internet Information Providers segment.

Market Cap: $348.62M

Commerce.com, Inc., with a market cap of US$348.62 million, has been reducing its losses by 12.5% annually over the past five years despite being unprofitable. The company's short-term assets exceed both its short and long-term liabilities, providing financial stability. Recent initiatives include launching new Shopify apps to enhance merchant capabilities and integrating with PayPal for AI-driven commerce solutions, indicating strategic growth efforts in e-commerce technology. While trading below estimated fair value and maintaining a satisfactory net debt to equity ratio of 35.7%, Commerce.com faces challenges with significant debt increase over the past five years and ongoing unprofitability without near-term profitability forecasts.

Caribou Biosciences (CRBU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for hematologic malignancies and autoimmune diseases, with a market cap of approximately $160.77 million.

Operations: The company generates revenue primarily from its efforts in developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies, totaling $9.30 million.

Market Cap: $160.77M

Caribou Biosciences, Inc., with a market cap of US$160.77 million, remains unprofitable as it advances its pipeline of genome-edited cell therapies. Despite reporting a net loss of US$27.55 million for the third quarter of 2025, the company holds sufficient short-term assets to cover liabilities and has no debt. Recent inclusion in the NASDAQ Biotechnology Index reflects growing recognition in the biotech sector. Clinical trials for CB-011 and vispacabtagene regedleucel are underway, with promising early results but notable adverse events reported. The company's cash runway is limited if free cash flow continues to decline at historical rates.

Seize The Opportunity

• Dive into all 334 of the US Penny Stocks we have identified here.
• Searching for a Fresh Perspective? AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.